Neuronetics, Inc. (STIM) FY2025 10-K Annual Report
Neuronetics, Inc. (STIM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Neuronetics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
- • New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
Management Discussion & Analysis
- • Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
- • Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
Risk Factors
- • Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
- • Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
Neuronetics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$149M
▲ +99.2% YoY
Net Income
-$39M
▲ +10.8% YoY
Gross Margin
48.5%
▼ -2384bp YoY
Operating Margin
-21.1%
▲ +2508bp YoY
Net Margin
-26.1%
▲ +3222bp YoY
ROE
-174.3%
▼ -1651bp YoY
Total Assets
$142M
▲ +0.5% YoY
EPS (Diluted)
$-0.59
▲ +57.2% YoY
Operating Cash Flow
-$20M
▲ +34.3% YoY
Source: XBRL data from Neuronetics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Neuronetics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.